Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

N.J. Liptrott; M. Giardiello; T.O. McDonald; S.P. Rannard; A. Owen

doi:10.2217/nnm-2017-0095

Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

N.J. Liptrott, M. Giardiello, T.O. McDonald, S.P. Rannard, A. Owen

Department of Materials

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir (LPV) dispersed into aqueous media display favorable pharmacokinetics.

Methods: The impact of LPV SDNs on the function and phenotype of primary human T cells and macrophages (primary sites of HIV replication) was investigated.

Results: LPV significantly increased IL-1β (ninefold higher than untreated cells; p = 0.045) and TNF-α (sixfold higher than untreated cells; p = 0.018) secretion from monocyte-derived macrophages, whereas LPV SDNs did not elicit these responses at comparable drug concentrations. LPV SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived macrophages.

Conclusion: The LPV SDN was demonstrated to exhibit comparable, or favorable behavior compared with an LPV aqueous solution in the employed biocompatibility assessments.

Original language	English
Pages (from-to)	2043-2054
Number of pages	12
Journal	nanomedicine
Volume	12
Issue number	17
DOIs	https://doi.org/10.2217/nnm-2017-0095
Publication status	Published - 14 Aug 2017

Keywords

antiretroviral nanoformulation
immunotoxicology
macrophages
T cells

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/nnm-2017-0095

Cite this

@article{66ba94e2133340b08c668a9b89600937,

title = "Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system",

abstract = "Aim: We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir (LPV) dispersed into aqueous media display favorable pharmacokinetics. Methods: The impact of LPV SDNs on the function and phenotype of primary human T cells and macrophages (primary sites of HIV replication) was investigated. Results: LPV significantly increased IL-1β (ninefold higher than untreated cells; p = 0.045) and TNF-α (sixfold higher than untreated cells; p = 0.018) secretion from monocyte-derived macrophages, whereas LPV SDNs did not elicit these responses at comparable drug concentrations. LPV SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived macrophages. Conclusion: The LPV SDN was demonstrated to exhibit comparable, or favorable behavior compared with an LPV aqueous solution in the employed biocompatibility assessments.",

keywords = "antiretroviral nanoformulation, immunotoxicology, macrophages, T cells",

author = "N.J. Liptrott and M. Giardiello and T.O. McDonald and S.P. Rannard and A. Owen",

year = "2017",

month = aug,

day = "14",

doi = "10.2217/nnm-2017-0095",

language = "English",

volume = "12",

pages = "2043--2054",

journal = "nanomedicine",

issn = "1743-5889",

publisher = "Taylor & Francis",

number = "17",

}

TY - JOUR

T1 - Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

AU - Liptrott, N.J.

AU - Giardiello, M.

AU - McDonald, T.O.

AU - Rannard, S.P.

AU - Owen, A.

PY - 2017/8/14

Y1 - 2017/8/14

N2 - Aim: We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir (LPV) dispersed into aqueous media display favorable pharmacokinetics. Methods: The impact of LPV SDNs on the function and phenotype of primary human T cells and macrophages (primary sites of HIV replication) was investigated. Results: LPV significantly increased IL-1β (ninefold higher than untreated cells; p = 0.045) and TNF-α (sixfold higher than untreated cells; p = 0.018) secretion from monocyte-derived macrophages, whereas LPV SDNs did not elicit these responses at comparable drug concentrations. LPV SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived macrophages. Conclusion: The LPV SDN was demonstrated to exhibit comparable, or favorable behavior compared with an LPV aqueous solution in the employed biocompatibility assessments.

AB - Aim: We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir (LPV) dispersed into aqueous media display favorable pharmacokinetics. Methods: The impact of LPV SDNs on the function and phenotype of primary human T cells and macrophages (primary sites of HIV replication) was investigated. Results: LPV significantly increased IL-1β (ninefold higher than untreated cells; p = 0.045) and TNF-α (sixfold higher than untreated cells; p = 0.018) secretion from monocyte-derived macrophages, whereas LPV SDNs did not elicit these responses at comparable drug concentrations. LPV SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived macrophages. Conclusion: The LPV SDN was demonstrated to exhibit comparable, or favorable behavior compared with an LPV aqueous solution in the employed biocompatibility assessments.

KW - antiretroviral nanoformulation

KW - immunotoxicology

KW - macrophages

KW - T cells

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85027704313&partnerID=MN8TOARS

U2 - 10.2217/nnm-2017-0095

DO - 10.2217/nnm-2017-0095

M3 - Article

SN - 1743-5889

VL - 12

SP - 2043

EP - 2054

JO - nanomedicine

JF - nanomedicine

IS - 17

ER -

Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this